Novartis Gets Expansion For Earlier Use Of Leqvio

Leqvio was approved by the US FDA for a broad label for high cholesterol in patients with an increased risk of heart disease, expanding beyond the initial approval for patients with ASCVD.

Novartis gained a new indication for Leqvio • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas